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Prague-Keele 1 (PK1) is a novel cytotoxic drug in which doxo-
rubicin is complexed with N-(2-hydroxypropyl) methacrylamide
(HPMA), a water-soluble polymer, by a peptidyl linker. The
rationale behind this compound is that whereas the vasculature of
the normal circulation prevents high molecular weight macro-
molecules from crossing cells by passive diffusion, tumour vessels
are ￿leaky￿, which allows the compound to enter the tumour
(Matsumura and Maeda, 1986). Once inside, they are poorly
cleared due to an inefficient lymphatic drainage system
(Matsumura and Maeda, 1986; Maeda and Matsumura, 1989).
PK1 is reported to be stable in plasma, thus potentially protecting
normal cells, but when taken up into tumours it is cleaved intra-
cellularly by lysosomal cysteine proteinases to release free
doxorubicin (Duncan et al, 1982). This modification can allow
much higher doses of doxorubicin to be administered while
reducing the potential for toxicity.
In this study, the pharmacokinetics of bound and free doxo-
rubicin were determined from plasma concentrations measured
during a phase I dose-ranging trial. Due to sampling and assay
limitations, few concentration data were available in patients who
received lower doses of this drug and it was therefore not possible
to analyse these sparse data by conventional, individual non-linear
regression. The aim was therefore to utilize a ￿population
approach￿, in which all data could contribute to the estimation of
pharmacokinetic parameters, to analyse the data. The population
approach aims to characterize factors that influence drug handling
in individual patients and to estimate both variability in pharmaco-
kinetics between individuals and residual error on concentration
measurements. When it was first introduced in the late 1970s it
was applied to sparse digoxin data collected from many patients
during routine therapeutic drug monitoring (Sheiner et al, 1977).
Since then, a number of computer methodologies have been
developed and the approach has been applied to data collected
using both sparse and extensive sampling protocols in a wide
range of therapeutic areas (Yuh et al, 1994). More recently, the
population approach has gained support from both the regulatory
authorities and the pharmaceutical industry as a useful tool in drug
development (Samara and Granneman, 1997; Tett et al, 1998).
MATERIALS AND METHODS
Protocol
Data were available from a phase I dose-ranging study of PK1 in
36 patients with histologically confirmed solid tumours considered
refractory or resistant to conventional treatments. The study was
approved by the Hospital Research and Ethics Committee and
each patient gave informed, written consent before they partici-
pated. All patients had a performance status of 2 or better on the
Eastern Co-operative Oncology Group—Zubrod—WHO scale and
had adequate bone marrow, hepatic and renal function as
evidenced by: neutrophils ‡ 2000 mm—3; platelets ‡ 100 000 mm—3;
haemoglobin ‡ 10 g l—1; bilirubin < 20 mmol l—1; aspartate trans-
aminase/alanine transaminase < 2 ´ the upper limit of normal;
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PK1 was supplied as a freeze-dried lyophilized powder in glass
vials containing 50 mg of doxorubicin-equivalent bound to
approximately 530 mg of polymer. This was reconstituted before
use with 25 ml 0.9% saline for injection to give a final concentra-
tion of 2 mg ml—1. Doses started at 20 mg m—2 and were escalated
according to clinical criteria using a modified Fibonacci scheme.
Three patients each received 20, 40, 80 and 120 mg m—2 and 6 each
received 180, 240, 280 and 320 mg m—1. Doses were administered
every 3 weeks until withdrawal from the study. PK1 was given
as a slow bolus over 5 min at low doses (20, 40 and 80 mg m—2),
as an infusion over 0.5—0.75 h at intermediate doses (120 and
180 mg m—2) and over 1—1.5 h at high doses (240, 280 and
320 mg m—2). Samples were withdrawn before the first dose, at
0.25 h during the infusion (doses > 80 mg m—2), at the end of the
infusion, then at the following times after the end of the infusion:
0.08, 0.16, 0.25, 0.33, 1, 2, 4, 8, 12 and 24 h. Further samples were
withdrawn at 48, 72, 96, 120, 168, 192 and 360 h in a number of
patients.
The following data were stored in a spreadsheet file for
analysis: patient identification number; dose (mg); infusion rate
(mg h—1); time from the start of the infusion; bound doxorubicin
concentration; performance status; age; height; weight; body
surface area; sex; concentrations of bilirubin, albumin, aspartate
aminotransferase, alanine aminotransferase and creatinine; and
estimated creatinine clearance (Cockcroft and Gault, 1976). A
similar file was then created containing the free doxorubicin
concentration measurements.
Assay
Bound and free doxorubicin concentrations were measured by high-
performance liquid chromatography (HPLC) with fluorescence
detection by the Bioanalytical Laboratory, Pharmacokinetics and
Metabolism Department, P & U, Nerviano, Italy. Details of the
assay method have been described in detail elsewhere (Fraier et al,
1995; Vasey et al, 1999). Limits of quantification for free and bound
doxorubicin were 0.38 ng ml—1 and 5.1 ng ml—1 respectively, and
interday assay coefficient of variation ranged from 7.8 to 10.8% for
free and 6.3 to 10.7% for bound doxorubicin.
Data analysis
The pharmacokinetics of bound and free doxorubicin were deter-
mined separately using a population approach in which concentra-
tions from all patients were analysed simultaneously. Models were
fitted to the data using the first order estimation method in the
package NONMEN (Version IV) (Beal et al, 1994) and FORTRAN
compilation was performed using FORTRAN PowerStation Version
1.0a. Precision was set at three significant figures. Drug input was
assumed to be zero order (constant rate infusion) and both mono-
exponential and biexponential elimination models were compared.
NONMEM estimated the pharmacokinetic parameters of the struc-
tural model, proportionality constants relating parameters (clear-
ance, volume of distribution, etc.) to clinical factors, and random
effects, that is interpatient and residual variabilities.
Interpatient variability in the parameter estimates was assumed
to correspond to a log-linear model, i.e.
Pik = PopPk ´ exp (hik)
Where Pik represents the kth pharmacokinetic parameter estimate
for the ith individual, PopPk are the population estimates of the
parameters (clearance, volume, etc.) and hik are the individual (i)
deviations from the population parameters (k). Covariance
between parameters was investigated during model development.
Three models were investigated for residual error:
Additive cij = predij + eij
Exponential cij = predij ´ exp (eij)
Combined cij = predij ´ exp (e1ij) + e2ij
where cij is the jth measured concentration in the ith individual and
eij represent the differences between each measured and predicted
(predij) concentration. These residual errors represent factors such
as intrapatient variability, assay error and sampling error.
Individual estimates of the pharmacokinetic parameters were
obtained for each patient following the population analysis using
the ￿posthoc￿ option in NONMEM. Half-lives were derived from
these parameters using standard equations.
Scatterplots of the pharmacokinetic parameters against the
available clinical data were examined for obvious trends, and an
all subsets multiple linear regression analysis of clinical factors
against the pharmacokinetic parameters was undertaken using the
statistical package MINITAB. Factors identified by these preliminary
approaches as possibly influencing the pharmacokinetics of
doxorubicin were then sequentially included in the population
model until the best model was identified. The following structure
was typically used:
PopPk = q1 ´ (1 + q2 ´ (factor1 — median)) ´
(1 + q3 ´ (factor2 — median)) ´￿´
where PopPk is the pharmacokinetic parameter (clearance, volume,
etc.), factor1, factor2, etc. represents the value of the clinical factor
under investigation and q are the parameters to be estimated.
A number of criteria were taken into account when comparing
models. Hierarchical models were compared statistically using a
likelihood ratio test. NONMEM produces an objective function
value (minus twice the log likelihood of the data) for each model.
The difference in these values between two models approximates
to a c2 distribution with degrees of freedom equal to the differ-
ence in the number of model parameters (Beal et al, 1994).
Significance was set at P < 0.005 (a reduction of > 7.9 for 1
degree of freedom). Differences between the measured and
population predicted concentrations (residuals) and also
weighted residuals (residuals standardized according to their
standard deviation) were plotted against time and predicted
concentration, and examined for outliers and trends that might
imply model misspecification. Profiles of measured, population
predicted and individual predicted concentrations against time
for each patient, standard errors of parameter estimates and
changes in estimates of intersubject and residual variability were
also assessed.
RESULTS
Patients
Concentration data were available from 33 patients (18 male)
whose ages ranged from 34 to 78 years (median 58 years) and
body surface areas from 1.4 to 2.2 m2 (median 1.7 m2). Seven
patients had a performance score of 0, 22 had a score of 1 and four
had a score of 2. Estimated creatinine clearance ranged from 31 to
100 AH Thomson et al
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ances below 50 ml min—1 (31, 44 and 44 ml min—1). Liver biochem-
istry tests were normal or only minimally disturbed. No patient
had elevated bilirubin concentrations, albumin concentrations
ranged from 31 to 47 g l—1 and the highest concentrations
of alanine aminotransferase and aspartate aminotransferase were
57 u l—1 and 62 u l—1 respectively.
Bound doxorubicin analysis
Three hundred and eighty-eight bound doxorubicin concentrations
were available for analysis. The number of concentrations per
patient ranged from 8 to 15 (median 11) and the last sample
time ranged from 8 to 385 h post dose. Concentration measure-
ments were available up to 24 h post dose in 17 patients and 29
concentrations were measured more than 90 h post dose.
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Table 1 Population pharmacokinetic parameter estimates arising from models fitted to bound doxorubicin concentration data
Basic model Model including weight Model including dose
Objective function value 1786.4 1774.8 1770.9
CL (l h–1) 0.194 0.192 0.194
% cv 8.0 8.2 8.2
Interpatient variability in CL 35% 34% 35%
V1 (1) 4.36 4.37 4.48
% cv 6.1 5.6 4.9
Influence of weight or dose on V1 0.0083 0.000737
% cv 43 27
Interpatient variability in V1 34% 31% 27%
V2 (1) 7.50 7.68 7.94
% cv 8.1 8.3 9.0
Interpatient variability in V2 45% 46% 43%
Q (l h–1) 0.696 0.681 0.685
% cv 11 12 11
Interpatient variability in Q 54% 51% 56%
Residual error 1 0.0150 0.0146 0.0162
Residual error 2 1.22 1.22 1.19
% cv = coefficient of variation of parameter estimate, CL = clearance, V1 = volume of the central compartment, V2 = volume of the peripheral compartment,
Q = intercompartmental clearance. N.B. Interpatient variability is expressed as a percentage coefficient of variation. The residual error model had the form
cij = predij x exp (error1ij) + error2ij and the covariate model took the form V1 = q1 x (1 + q2 x factor) where q represents the parameter to be estimated and factor
represents (dose – median dose) or (weight – median weight).
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Figure 1 Population predicted versus measured bound doxorubicin concentrations arising from the basic model. The data from Patient 26 are represented by
solid circles102 AH Thomson et al
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yA biexponential elimination model was superior to a mono-
exponential model in both objective function value (difference of
229) and weighted residual plots. Allowing covariance between
the parameters further improved the fit and residual error was best
described by the combined model.
Weighted residuals > 3 are often regarded as outliers (Beal et
al, 1994) and one concentration with a weighted residual of 15
was removed from the data set and all subsequent analyses. This
was a measurement of 81 mg ml—1 after 0.25 h of a 1 h infusion.
Since the concentration at the end of the infusion was 86 mg ml—1,
the initial result (which was 3—4 times higher than concentrations
measured at 0.25 h in other patients on the same dose) was highly
unlikely.
The population parameter estimates arising from the basic
pharmacokinetic model are presented in Table 1. In most patients
these population estimates provided a good fit of the individual
data, however, the bound concentrations measured in patient 26
were substantially lower than those predicted by the population
model. This suggested that this patient was an outlier (Figure 1). In
all cases the individual parameter estimates fitted the measured
concentrations well, although in five patients small fluctuations
in bound doxorubicin concentration were observed in the first
10—20 min after the end of the infusion.
Individual estimates of clearance (CL), volume of the central
compartment (V1), volume of the peripheral compartment (V2)
and intercompartmental clearance (Q) were plotted against each
patient￿s identification number (ID), dose and clinical characteris-
tics. No obvious trends were seen and there was no evidence of
dose-dependency in clearance. Multiple linear regression analysis
identified creatinine concentration and creatinine clearance as
possibly influencing clearance, and weight and dose as influencing
volume, but in all cases the explanatory power of these variables
was very low (only 11—15% of the variability in CL or V1).
In the NONMEM analysis indicators of neither renal function nor
sex significantly influenced CL, V1 or V2 when included in the
population model, however, both dose and weight had statistically
significant effects on V1. This influence of dose on V1 persisted
even if patient 26 was removed from the data set. A small
improvement in fit was obtained when both factors were included
in the model but this did not achieve the predetermined level of
significance. Population estimates arising from the basic model
and the models including weight and dose are shown in Table 1.
The model including dose found that V1 changed by 0.07% for
every 1 mg above and below 345 mg (the median dose) and
produced population estimates of V1 that ranged from 3.4 l at
33 mg (the lowest dose) to 5.6 l at 670 mg (the highest dose). In
the model including weight, V1 changed by 0.8% for every kg
above and below 67 kg which resulted in an estimated range of
3.4—5.7 l across the weight range of 41—103 kg. Intersubject
coefficient in variation in V1 fell from 34% to 31% when weight
was included and to 27% when dose was included.
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Table 2 Summary of the covariate models tested for free doxorubicin
Model Covariate OBJ Compared DIFF Significance
with model
1 None 2269.5 0.0
2 Dose on V1 2252.1 1 17.4 P < 0.005
3 Weight on V1 2263.6 1 5.9 P < 0.05
4 BSA on V1 2264.9 1 4.6 P < 0.05
5 Height on V1 2265.1 1 4.4 P < 0.05
6 Dose on V2 2259.3 1 10.2 P < 0.005
7 Weight on V2 2265.3 1 4.3 P < 0.05
8 BSA on V2 2262.4 1 7.1 P < 0.01
9 Height on V2 2244.4 1 25.1 P < 0.005
10 Albumin on CL 2269.5 1 0.0 NS
11 Dose on V1, height on V2 2227.4 9 17.0 P < 0.005
12 Dose on V2, height on V2 2217.8 9 26.6 P < 0.005
13 Dose on V1, 2204.0 12 13.8 P < 0.005
height on V2, dose on V2
OBJ = objective function value, DIFF = difference in objective function values (> 7.9 is significant at P < 0.005), V1 = volume of the central
compartment, V2 = volume of the peripheral compartment, CL = clearance, BSA = body surface area.
Table 3 Population pharmacokinetic parameter estimates of free
doxorubicin
Basic model Full model
(model 1, Table 2) (model 13, Table 2)
Objective function value 2269.5 2204.0
CL (1 h–1) 179 180
% cv 7.8% 10%
Interpatient variability on CL 35% 33%
V1 (1) 1340 1450
% cv 14% 13%
Influence of dose on V1 0.0013
% cv 29%
Interpatient variability on V1 99% 58%
V2 (1) 16900 21 300
% cv 11% 8.7%
Influence of dose on V2 –0.0013
% cv 40%
Influence of height on V2 2.95
% cv 17%
Interpatient variability on V2 74% 57%
Q (l h–1) 8310 6950
17% 12%
Interpatient variability on Q 159% 128%
Residual error 43% 40%
% cv = coefficient of variation of parameter estimate, CL = clearance,
V1 = volume of the central compartment, V2 = volume of the peripheral
compartment, Q = intercompartmental clearance. N.B. Interpatient variability
is expressed as a percentage coefficient of variation. The residual error
model had the form cij = predij x exp (errorij) and the covariate models took
the form P = q1 x (1 + q2 x factor) where P is V1 or V2, q represents the
parameter to be estimated and factor represents (dose – median dose) or
(height – median height).The population estimate of clearance using the dose model was
0.194 l h—1 (Table 1) with individual estimates ranging from 0.147
to 0.647 l h—1. Derived Vss (V1 + V2) had a median estimate of
12 l (range 7.3—52 l). Patient 26 had the highest estimates of all the
individual parameters. Derived distribution half-life had a median
value of 2.7 h (range 1.2—5.1 h) and elimination half-life had a
median value of 49 h (range 32—81 h). Figure 2A illustrates the
concentration-time profiles for four typical subjects together with
the predicted concentrations arising from the population and the
￿posthoc￿ individual parameter estimates.
Population analysis of free doxorubicin concentrations
Data were available from 33 patients, and comprised 379 concen-
trations with a median of 11 samples per patient (range 6—15). The
time of the last detectable concentration ranged from 1 to 385 h
post dose and in five patients was 12 h post dose or less. Twenty-
nine samples were above the limit of quantification beyond 90 h
post dose. One outlying point, an end of infusion concentration of
515.85 ng ml—1, was removed from the analysis. This result was
inconsistent with subsequent measurements of 183 ng ml—1 (or
less) for samples beyond 5 min after the end of the infusion.
Free doxorubicin data were also best described by a biexponen-
tial elimination model. An exponential model proved adequate to
describe the residual error and it was not possible to estimate
covariance between parameters. Population parameter estimates
obtained from the basic pharmacokinetic model indicated that free
doxorubicin ￿clearance￿ at 179 l h—1 was 1000 times the clearance
of bound doxorubicin. This apparent clearance probably reflected
the small amount of free doxorubicin available when the injection
was administered. Although this model provided a satisfactory fit
to most data, examination of the individual plots suggested an
underestimation of some initial (peak) concentrations at doses up
to 120 mg m—2. However, good predictions of peak concentrations
were achieved at higher doses.
No clear trends were identified when individual estimates of
apparent CL, V1, V2 and Q were plotted against clinical character-
istics and there was no evidence of dose dependency in CL.
Multiple regression analysis suggested that albumin might influ-
ence apparent CL, dose and bilirubin might influence apparent V1
and dose and height might influence apparent V2. These factors,
and body surface area, were therefore investigated using NONMEM
and Table 2 summarizes the results. Statistically significant
improvements in fit (P < 0.005) were observed with dose on V1
and both dose and height on V2. Smaller effects (P < 0.05) were
observed with weight, height and body surface area on V1 and
weight and body surface area on V2. When factors were combined
neither weight nor body surface area improved the fits obtained
using dose on V1 and V2 but the combination of dose and height
on V2 produced a statistically significant effect. Table 3 shows the
parameter estimates from the basic model and the full model with
dose on V1 and both dose and height on V2. These estimates indi-
cated a 0.13% change in both V1 and V2 with a 1 mg change in
dose from 345 mg and a 29.5% change in V2 with a 0.1 m change
in height from 1.7 m. Figure 2B illustrates the measured, popula-
tion predicted and individual predicted free doxorubicin concen-
tration—time profiles obtained for patients 3, 9, 16 and 24 using
this model.
PK1 doxorubicin population pharmacokinetics 105
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Figure 3 Ratio of bound to free doxorubicin at the time of the first sample. (Patient 26 is represented by a solid circle.) N.B. The first sample was typically
drawn at 5 min for doses < 200 mg and 15 minutes for doses > 200 mgIndividual estimates of apparent CL ranged from 107 to
282 l h—1 but, due to the paucity of concentration data beyond the
distribution phase, individual estimates for patients on low doses
(< 80 mg) were essentially unchanged from the population values.
Derived apparent Vss had a median estimate of 22 883 l (indi-
vidual range 2978—43 189 l), the median derived distribution half-
life was 0.13 h (range 0.08—1.4 h) and derived elimination half-life
had a median of 85 h (range 10—168 h). Patient 26 was again an
outlier but in this case had concentrations of free doxorubicin that
were consistently higher than predicted by the population model
and the lowest estimates of apparent V1 and V2. Although free
doxorubicin was generally detectable at the first time point in all
patients, the ratio of bound to free doxorubicin in patient 26 was
much lower than in other subjects (as illustrated in Figure 3).
DISCUSSION
A population approach has been used to analyse bound and free
doxorubicin data generated during a phase I clinical study of PK1
in patients with solid tumours. Although it has been suggested that
this methodology may be useful for dose escalation designs where
many concentrations fall below assay limits (Schoemaker and
Cohen, 1996), many population studies to date have focused on
sparse data collected during Phase III of drug development or
routine clinical practice (Samara and Granneman, 1997). The
population approach has been applied in cancer chemotherapy,
especially for drugs such as carboplatin (Chatelut et al, 1995),
docetaxel (Bruno et al, 1996) and etoposide (Nguyen et al, 1998)
and in the analysis of phase I data (Chabot et al, 1995; Launay
Iliadis et al, 1995). Limited sampling strategies employing
Bayesian approaches have also been used to estimate population
parameters during early drug development (Jodrell et al, 1994;
Reyno et al, 1995; McLeod et al, 1996; Piscitelli et al, 1997). The
population approach has particular relevance to phase I drug
development in cancer chemotherapy due to the data handling
problems that are inherent when very low initial doses (1/10 of the
LD10) are used. Indeed, attempts were made to analyse the low
dose data from the present study using conventional non-linear
regression but this proved unsuccessful due to lack of information
about the elimination phase. Because the population approach
analyses all the data simultaneously, such sparse or incomplete
data were not simply discarded but contributed to the estimation of
pharmacokinetic parameters. In addition, this initial analysis
provides a basis for future studies in which the population model
can be developed and refined as more data become available.
Bound doxorubicin concentration measurements were best
described by a biexponential disposition model and in most cases
the population mean parameter estimates provided good predic-
tions of the measured concentrations. There was no evidence of
double peaks or redistribution as has been observed with pegyl-
ated-liposomal doxorubicin (Amantea et al, 1997). Clearance was
well defined and the inter-individual variability was low at 26%.
In contrast, interpatient coefficients of variation in intercompart-
mental clearance and volume of the peripheral compartment were
higher at 54% and 45% respectively.
Scatterplots and multiple linear regression analysis failed to
identify clear relationships between clinical characteristics and
pharmacokinetic parameters. Doxorubicin is principally cleared
by hepatic and biliary routes and reduced clearance has previously
been demonstrated in patients with abnormal liver biochemistry
tests (Piscitelli et al, 1993). However, the lack of significant clin-
ical factors was not unexpected because the number of patients
was relatively small and all had essentially normal renal and
hepatic function. Both dose and weight influenced V1 when
included as single covariates but combining these factors offered
no significant advantage. In contrast to the results of Amantea et al
(1997) in a larger group of 43 patients who received pegylated-
liposomal doxorubicin, body surface area was not found to influ-
ence the clearance of PK1, nor was clearance reduced in female
patients, as previously shown by Dobbs et al (1995) with standard
doxorubicin. However, a larger number of subjects would be
required to investigate these influences properly.
Due to the relative paucity of data, free doxorubicin concentra-
tions were more difficult to interpret than bound concentrations.
Although a biexponential model appeared to describe the data well
overall, there was an underestimation of peak concentrations in
some patients at low doses which may suggest a model misspecifi-
cation problem or a formulation effect. Previous studies have
identified triexponential elimination after the administration of
doxorubicin (Bronchud et al, 1990; Piscitelli et al, 1993; Dobbs
et al, 1995; Jaquet et al, 1996). However, when data from two
patients who received the highest dose, and had the highest
number of concentration measurements, were analysed individu-
ally it was not possible to characterize the parameters of a triexpo-
nential model. Moreover, the initial distribution half-life of 8 min
was similar to previous reports in the range of 3—5 min (Jaquet
et al, 1996). Inclusion of dose as a factor affecting apparent V1
produced population predicted concentrations that were closer to
the measured concentrations suggesting that this problem might be
dose-related. Figure 3 shows a trend towards higher bound to free
doxorubicin ratios and much wider variability at higher doses.
This suggests that the apparent dose effects on both bound and free
doxorubicin may be related to variability in the formulation.
The only clinical factor found to influence free doxorubicin
pharmacokinetics was height, which had a small effect on apparent
V2. The elimination half-life of 85 h identified in this analysis was
longer than the typical values of 20—50 h reported in many studies
with doxorubicin (Bronchud et al, 1990; Piscitelli et al, 1993;
Dobbs et al, 1995; Jaquet et al, 1996). It is possible that these
differences are influenced by sampling strategy. In most of the
previous studies samples were collected up to 48 h after the dose
whereas in the present study samples were collected for up to 15
days. Thirty-two free doxorubicin measurements were available
beyond 48 h post dose which might permit identification of a
longer elimination half-life. Alternatively, the slow elimination
may have been influenced by release of free doxorubicin from the
PK1 complex or from cells.
Parameter estimates obtained from the free doxorubicin analysis
were 1000 times higher than the bound estimates, reflecting the
1000-fold difference in concentrations and the very low availability
of free doxorubicin in the formulation. The ratio of bound to free
doxorubicin concentration at the time of the first sample was highly
variable, especially at higher doses (Figure 3) and tended to
increase then decrease during the dosage interval. This probably
reflects the differences in pharmacokinetic profiles between the
two species. Free doxorubicin had a very rapid distribution phase
with a half-life of 8 min while the distribution of bound doxoru-
bicin was slower with a median estimate of 2.7 h. In contrast, elim-
ination half-lives were shorter for bound doxorubicin (49 h
compared to 85 h). These observations, coupled to the detection of
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of the infusion) and the highly variable ratio, suggest that very
small, but variable, amounts of free doxorubicin were present in
the formulation at the time of administration.
One outlier was identified who had unexpectedly high free
doxorubicin concentrations (population predicted peak 82 ng ml—1,
measured peak 441 ng ml—1) and low bound concentrations (popu-
lation predicted peak 104.3 mg ml—1, measured peak 18.4 mg ml—1).
These unusual concentrations were associated with highest esti-
mates of bound and lowest estimates of free parameters and prob-
ably contributed to the high intersubject variabilities in volume
that were identified. The results for this patient suggest that some
dissociation of the compound had occurred or that there was rapid
cleavage of a small amount of PK1 at the time of administration.
However, the latter explanation is unlikely because all the free
doxorubicin profiles clearly followed a biexponential decline and
there was no evidence of increasing concentrations after the infu-
sion. The shape of the free doxorubicin profiles also suggested that
free doxorubicin was not being leached from cells after intra-
cellular cleavage. If that had been the case, a gradual increase in
concentration might have been expected rather than simply a
decline.
In summary, the pharmacokinetics of bound and free doxo-
rubicin were determined from data collected during a phase 1
study of PK1. The population methodology allowed data from all
patients, including those for whom only a few concentrations were
available, to contribute to parameter estimation. Concentrations of
bound and free doxorubicin differed by a factor of 1000 and this
translated into population clearance estimates of 0.194 1 h—1 for
bound and 180 1 h—1 for free doxorubicin. There was no evidence
of dose dependency in clearance and although no clinical factors
strongly influenced the clearances of bound or free doxorubicin,
none of the patients had evidence of severe renal or, more impor-
tantly, hepatic impairment.
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